Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?

As drug discovery moves from trial-and-error to digital simulation, choosing between Recursion Pharmaceuticals (NASDAQ:RXRX) and Schrödinger (NASDAQ:SDGR) depends on whether you prefer a biotech-heavy or software-focused investment approach.Recursion seeks to industrialize drug discovery by using massive datasets and artificial intelligence to map biology. Schrödinger provides the computational platform used by thousands of researchers, combining a software-as-a-service model with high-upside drug development programs. Both companies represent the frontier of the movement to make medicine faster and cheaper to develop.Recursion is building an industrialized engine for medicine. It operates among biotech stocks, selling access to its proprietary platform and pursuing joint development with major partners like Roche (OTC:RHHBY) and Bayer (OTC:BAYZF). The company uses massive datasets and automation to identify new drug candidates. This customer concentration adds a layer of risk to the business, as it depends on a few large entities for all of its near-term revenue.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool